Evidence method
Level · gp.fundamentals.cash
$11.1B · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANG-PD · Mar 31, 2021
American National Group Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001039828-21-000033Insurance
Evidence method
Yoy · gp.fundamentals.net_income
16.36% · CORE · VALID
Evidence method
Yoy · gp.insurance.premiums
72.40% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History51 statesSelf-history eligible
Sep 30, 20214/4 normalizedLevel 3Dec 31, 20214/4 normalizedLevel 3Mar 31, 20224/4 normalizedLevel 3Jun 30, 20223/3 normalizedLevel 3Sep 30, 20224/4 normalizedLevel 3Dec 31, 20224/4 normalizedLevel 3Mar 31, 20234/4 normalizedLevel 3Jun 30, 20234/4 normalizedLevel 3Sep 30, 20234/4 normalizedLevel 3Dec 31, 20234/4 normalizedLevel 3Mar 31, 20243/3 normalizedLevel 3Jun 30, 20244/5 normalizedLevel 3Sep 30, 20244/5 normalizedLevel 3Dec 31, 20244/5 normalizedLevel 3Mar 31, 20254/5 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20254/5 normalizedLevel 3Dec 31, 20255/6 normalizedLevel 3Mar 31, 20264/5 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- $9.1B
- Current
- $11.1B
- Delta
- $2.0B
- Previous
- 172.85%
- Current
- 16.36%
- Delta
- -156.50%
- Previous
- 67.34%
- Current
- 72.40%
- Delta
- 5.06%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.